Christine Tsingos
Envista HoldingsAbout Christine Tsingos
Independent director at Envista Holdings (NVST), age 66, serving since 2019. Former EVP & CFO of Bio-Rad Laboratories (2002–May 2019), bringing deep finance, accounting, and audit oversight experience; designated an audit committee financial expert and currently chairs Envista’s Audit Committee while serving on Compensation and Finance Committees . Current external public boards include Onto Innovation Inc. and Varex Imaging Corporation; previously a director at Telesis Bio Inc. .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Bio-Rad Laboratories, Inc. | EVP & Chief Financial Officer | 2002 – May 2019 | Led finance and accounting; experience supports audit committee chair role and financial expert designation |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Onto Innovation Inc. | Director | Current | Not disclosed in NVST proxy |
| Varex Imaging Corporation | Director | Current | Not disclosed in NVST proxy |
| Telesis Bio Inc. | Director | Prior | Not disclosed in NVST proxy |
Board Governance
- Independence: Board determined Ms. Tsingos is independent under NYSE and SEC rules .
- Committee assignments: Audit Committee (Chair), Compensation Committee (Member), Finance Committee (Member) .
- Audit Committee quality: All members are audit committee financial experts; Audit met 8 times in 2024 .
- Board activity/attendance: Board met 9 times in 2024; all directors attended at least 75% of Board and applicable committee meetings; all attended the 2024 Annual Meeting .
- Leadership structure: Separate Chair and CEO; independent Board Chair (Scott Huennekens) leads executive sessions of non-management and independent directors; independent directors meet regularly, with at least annual executive sessions .
- Governance guardrails: Directors limited to serving on no more than four other public company boards; robust related-party transaction policy with Nominating & Governance Committee oversight .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Cash Retainer (Non-Employee Director) | $100,000 | Paid quarterly |
| Audit Committee Chair Cash Retainer | $25,000 | Additional for chair role |
| Meeting Fees | $2,000 per meeting | Only for meetings beyond 20 per year (aggregate Board+committees), incl. Finance Committee |
| Cash Earned (2024) – Christine Tsingos | $135,000 | Sum of retainers and any applicable fees |
Performance Compensation
| Component | 2024 Value | Grant Mechanics / Vesting | Future Change |
|---|---|---|---|
| Annual Equity Award (RSUs) | $185,060 | Granted 5/21/2024; 10,085 RSUs determined at $18.35 grant-date price; vests 5/21/2025; settlement on vest or deferral election | Annual equity retainer increased to $200,000 starting 2025 |
- NVST director pay uses time-based RSUs; no performance metrics are tied to director compensation (equity is dollar-denominated, one-year vesting) .
Other Directorships & Interlocks
| Company | Sector Proximity to NVST | Notes |
|---|---|---|
| Onto Innovation Inc. | Semiconductors/inspection | Current directorship |
| Varex Imaging Corporation | Medical imaging | Current directorship |
| Telesis Bio Inc. | Life sciences tools | Prior directorship |
- Board service cap: Corporate governance guidelines limit directors to four public company boards; Ms. Tsingos’ external roles are within this limit .
Expertise & Qualifications
- Finance and accounting leadership; audit oversight; SEC reporting; capital markets experience (as Bio-Rad CFO) .
- Designated audit committee financial expert; chairs Audit Committee .
- Public company board experience spanning medical technology and life sciences tools .
- Independent director status under NYSE/SEC rules .
Equity Ownership
| Item | Amount | Detail |
|---|---|---|
| Beneficial Ownership – Shares | 40,150 | Includes vested but unreleased RSUs and RSUs vesting within 60 days; also includes 9,860 shares of Common Stock held directly |
| Ownership as % of Shares Outstanding | <1% | Company reports “*” less than 1% of outstanding shares |
| Unvested RSUs (as of 12/31/2024) | 10,085 | From the 2024 annual grant; vests 5/21/2025 |
| Hedging/Pledging | Prohibited | Directors may not pledge NVST stock or engage in derivatives/hedging |
| Director Stock Ownership Guideline | 5x cash retainer | Must reach 5× annual cash retainer within 5 years; beneficial ownership counts RSUs; compliance status for individual directors not disclosed |
Governance Assessment
- Strengths: Independent director; Audit Chair with financial expert designation; strong committee activity (Audit met 8× in 2024); robust anti-hedging/anti-pledging and stock ownership policies; no related-party transactions disclosed for 2024 .
- Alignment: Director compensation mix emphasizes equity (RSUs) with one-year vesting; her 2024 compensation totaled $320,060, with $185,060 equity and $135,000 cash, consistent with NVST’s design of at least 50% equity for directors .
- Shareholder signals: Historical Say-on-Pay support remains high (93.9% in 2024; 94.3% in 2023; 95.9% in 2022), indicating general investor confidence in compensation governance; while NEO-focused, this reflects broader compensation oversight quality by the Board and committees .
- Potential conflicts/red flags: None disclosed—no related-party transactions, hedging, or pledging; external board service within governance cap; attendance thresholds met; no meeting fee over-use disclosed .
- Forward changes: 2025 increase in director equity retainer to $200,000 modestly raises equity alignment without introducing performance risk; monitor overall board workload and committee demands (Audit, Compensation, Finance) for sustained effectiveness .
RED FLAGS: None disclosed related to related-party transactions, pledging/hedging, or attendance. Continue monitoring external board commitments and evolving committee workload for potential capacity risks .